Vol. 1 No. 11: Thalidomide in the treatment of multiple myeloma, Sydney, 10 April 2005

Articles

• Introduction

  Douglas E. Joshua

  https://doi.org/10.4081/hmr.v1i11.349

  Published: June 5, 2009

  138

  PDF: 106

  • PDF

• Thalidomide alone or in combination: results in refractory patients

  Jesús F. San Miguel

  https://doi.org/10.4081/hmr.v1i11.350

  Published: June 5, 2009

  222

  PDF: 349

  • PDF

• Retrospective study of thalidomide plus dexamethasone versus conventional chemotherapy in the relapsed multiple myeloma patient and the study of melphalan and prednisone versus melphalan, prednisone, and thalidomide

  Mario Boccadoro

  https://doi.org/10.4081/hmr.v1i11.351

  Published: June 5, 2009

  143

  PDF: 154

  • PDF

• The Intergroupe Francophone du Myélome experience with thalidomide

  Jean-Luc Harousseau, Michel Attal, Thierry Facon, Ibrahim Yakoub-Agha

  https://doi.org/10.4081/hmr.v1i11.352

  Published: June 5, 2009

  181

  PDF: 267

  • PDF

• Thalidomide plus dexamethasone as initial therapy for multiple myeloma: overview of Mayo Clinic and Eastern Cooperative Oncology Group experience

  Robert A. Kyle, Vincent Rajkumar

  https://doi.org/10.4081/hmr.v1i11.353

  Published: June 5, 2009

  143

  PDF: 259

  • PDF

• Panel Discussion

  Dr. Joshua

  https://doi.org/10.4081/hmr.v1i11.354

  Published: June 5, 2009

  116

  PDF: 186

  • PDF